These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 12372943)

  • 61. Recombinant erythropoietin improves exercise capacity in anemic hemodialysis patients.
    Robertson HT; Haley NR; Guthrie M; Cardenas D; Eschbach JW; Adamson JW
    Am J Kidney Dis; 1990 Apr; 15(4):325-32. PubMed ID: 2321645
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Erythropoietin and cardiovascular risk.
    Allegra V; Martimbianco L; Mengozzi G; Vasile A
    Blood Purif; 1995; 13(6):301-13. PubMed ID: 8821194
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Changes in anemia management and hemoglobin levels following revision of a bundling policy to incorporate recombinant human erythropoietin.
    Hasegawa T; Bragg-Gresham JL; Pisoni RL; Robinson BM; Fukuhara S; Akiba T; Saito A; Kurokawa K; Akizawa T
    Kidney Int; 2011 Feb; 79(3):340-6. PubMed ID: 20962740
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Subcutaneous recombinant human erythropoietin in patients on CAPD.
    Lye WC; Lee EJ
    Adv Perit Dial; 1991; 7():285-7. PubMed ID: 1680447
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Red blood cell membrane lipid peroxidation and resistance to erythropoietin therapy in hemodialysis patients.
    Gallucci MT; Lubrano R; Meloni C; Morosetti M; Manca di Villahermosa S; Scoppi P; Palombo G; Castello MA; Casciani CU
    Clin Nephrol; 1999 Oct; 52(4):239-45. PubMed ID: 10543326
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Reduced serum hydroxyl radical scavenging activity in erythropoietin therapy resistant renal anemia.
    Hirayama A; Nagase S; Gotoh M; Ueda A; Ishizu T; Yoh K; Aoyagi K; Terao J; Koyama A
    Free Radic Res; 2002 Nov; 36(11):1155-61. PubMed ID: 12592667
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Clinical and blood rheologic stability in erythropoietin-treated predialysis patients.
    Brown CD; Friedman EA
    Am J Nephrol; 1990; 10 Suppl 2():29-33. PubMed ID: 2260615
    [TBL] [Abstract][Full Text] [Related]  

  • 68. RBC improved survival due to recombinant human erythropoietin explains effectiveness of less frequent, low dose subcutaneous therapy.
    Schwartz AB; Kahn SB; Kelch B; Kim KE; Pequignot E
    Clin Nephrol; 1992 Nov; 38(5):283-9. PubMed ID: 1451342
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Ultrapure dialysis water obtained with additional ultrafilter may reduce inflammation in patients on hemodialysis.
    Di Iorio B; Di Micco L; Bruzzese D; Nardone L; Russo L; Formisano P; D'Esposito V; Russo D
    J Nephrol; 2017 Dec; 30(6):795-801. PubMed ID: 28840494
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Comparison of intramuscular versus subcutaneous erythropoietin for the treatment of anemia in CAPD patients.
    Abreo K; Lubom JA; Collier L; Fleming D; Work J
    Adv Perit Dial; 1994; 10():124-8. PubMed ID: 7999809
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effects of recombinant human erythropoietin (rHuEPO) on nutritional status of hemodialysis patients: investigation of direct anabolic effects of rHuEPO.
    Usuba T; Kuno T; Higuchi T; Kikuchi F; Nagura Y; Kanmatsuse K; Takahashi S
    Nihon Jinzo Gakkai Shi; 1994 Nov; 36(11):1288-95. PubMed ID: 7853762
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A preliminary study of the effects of correction of anemia with recombinant human erythropoietin therapy on sleep, sleep disorders, and daytime sleepiness in hemodialysis patients (The SLEEPO study).
    Benz RL; Pressman MR; Hovick ET; Peterson DD
    Am J Kidney Dis; 1999 Dec; 34(6):1089-95. PubMed ID: 10585319
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Management of anemia in erythropoietin-resistant hemodialysis patients.
    Dar Santos AE; Shalansky KF; Jastrzebski JP
    Ann Pharmacother; 2003 Dec; 37(12):1768-73. PubMed ID: 14632604
    [TBL] [Abstract][Full Text] [Related]  

  • 74. ACE inhibitors or angiotensin II receptor blockers in dialysed patients and erythropoietin resistance.
    Saudan P; Halabi G; Perneger T; Wasserfallen JB; Wauters JP; Martin PY;
    J Nephrol; 2006; 19(1):91-6. PubMed ID: 16523432
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Is erythropoietin a survival factor for red blood cells?
    Polenakovic M; Sikole A
    J Am Soc Nephrol; 1996 Aug; 7(8):1178-82. PubMed ID: 8866410
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The effect of hemodialysis and acetate-free biofiltration on anemia.
    Eiselt J; Racek J; Opatrny K
    Int J Artif Organs; 2000 Mar; 23(3):173-80. PubMed ID: 10795662
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The required dose of erythropoietin during renal anaemia treatment is related to the degree of impairment in erythrocyte deformability.
    Linde T; Sandhagen B; Wikström B; Danielson BG
    Nephrol Dial Transplant; 1997 Nov; 12(11):2375-9. PubMed ID: 9394325
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Reduced requirement for erythropoietin with quotidian hemodialysis therapy.
    Klarenbach S; Heidenheim AP; Leitch R; Lindsay RM;
    ASAIO J; 2002; 48(1):57-61. PubMed ID: 11814098
    [TBL] [Abstract][Full Text] [Related]  

  • 79. National cooperative rHu erythropoietin study in patients with chronic renal failure: a phase IV multicenter study. Report of National Cooperative rHu Erythropoietin Study Group.
    Nissenson AR
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):24-33. PubMed ID: 1928075
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Experience with the JMS fully automated dialysis machine.
    Tsuchiya S; Moriishi M; Takahashi N; Watanabe H; Kawanishi H; Kim ST; Masaoka K
    ASAIO J; 2003; 49(5):547-53. PubMed ID: 14524562
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.